Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.43 |
| ▸ | GART | P22102 | 5/20 | 0.41 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 2/20 | 0.38 |
| ▸ | ATIC | P31939 | 2/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.37 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2150241 | 0.98 | GART (0.42) | NOD1GARTSLC15A2SLC6A5TYMS | |
| SCHEMBL14167462 | 0.97 | NOD1 (0.46) | NOD1GARTSLC6A5TYMSATIC | |
| SCHEMBL14167513 | 0.97 | NOD1 (0.46) | NOD1GARTSLC6A5TYMSATIC | |
| SCHEMBL2157922 | 0.90 | NOD1 (0.39) | NOD1GARTSLC15A2SLC6A5TYMS | |
| SCHEMBL19051472 | 0.89 | SLC6A5 (0.39) | GARTSLC6A5GNPAT | |
| SCHEMBL31265388 | 0.87 | SLC15A2 (0.44) | GARTSLC15A2TYMSATICFOLH1 | |
| SCHEMBL29870996 | 0.87 | SLC15A2 (0.44) | GARTSLC15A2TYMSATICFOLH1 | |
| SCHEMBL7807950 | 0.86 | SLC15A2 (0.49) | GARTSLC15A2FOLH1NAALAD2 | |
| SCHEMBL30781162 | 0.86 | SLC6A5 (0.37) | SLC6A5FOLH1 | |
| SCHEMBL19051570 | 0.85 | NAALAD2 (0.39) | SLC15A2FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029325-B2 | Amylin analogues and pharmaceutical compositions thereof | NOVO NORDISK A/S (DK) | 2015-05-12 | — | — | US | disclosed |
| US-8722849-B2 | Polypeptides | NOVO NORDISK A/S (DK) | 2014-05-13 | — | — | US | disclosed |
| EP-2718314-A2 | POLYPEPTIDES | Novo Nordisk A/S (DK) | 2014-04-16 | — | — | EP | disclosed |
| EP-2718316-A1 | POLYPEPTIDES | Novo Nordisk A/S (DK) | 2014-04-16 | — | — | EP | disclosed |
| EP-2718315-A2 | POLYPEPTIDES | Novo Nordisk A/S (DK) | 2014-04-16 | — | — | EP | disclosed |
| US-20140018286-A1 | AMYLIN ANALOGUES AND PHARMACEUTICAL COMPOSITIONS THEREOF | NOVO NORDISK A/S (DK) | 2014-01-16 | — | — | US | disclosed |
| US-8575090-B2 | Amylin analogues and pharmaceutical compositions thereof | NOVO NORDISK A/S (DK) | 2013-11-05 | — | — | US | disclosed |
| US-20130059770-A1 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2013-03-07 | — | — | US | disclosed |
| US-20130005646-A1 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2013-01-03 | — | — | US | disclosed |
| WO-2012168430-A2 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012168432-A1 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012168431-A2 | POLYPEPTIDES | NOVO NORDISK A/S (DK) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005646-A1 | POLYPEPTIDES | IAPP, GLP1R, GIPR | NOD1 3819/4885GART 1699/4885SLC15A2 3036/4885 |
| US-20140018286-A1 | AMYLIN ANALOGUES AND PHARMACEUTICAL COMPOSITIONS THEREOF | IAPP, GLP1R, GCG | NOD1 2245/4885GART 164/4885SLC15A2 2814/4885 |
| US-20130059770-A1 | POLYPEPTIDES | IAPP, GLP1R, GIPR | NOD1 3819/4885GART 1699/4885SLC15A2 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.